Fresenius stock: Fourteen analysts set a EUR 55.66 target for Fresenius stock

Published on 10/19/2026 at 16:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

P/E was 16.31 on October 19, 2026. Fresenius stock costs EUR 44.82 on October 19, 2026, down 0.58 percent versus the Xetra close.

Analyst view and valuation

On October 16, 2026, Deutsche Bank kept its Buy rating and the 14-analysis consensus averaged EUR 55.66.
Fresenius had a P/E of 16.31 and market capitalization of EUR 25.3 billion on October 19, 2026.
Fresenius stock costs EUR 44.82 at Lang & Schwarz on October 19, 2026 at 4:39 p.m. CEST, 0.58 percent below the Xetra close of October 16, 2026.
Fresenius is scheduled to publish its third-quarter 2026 results on November 4, 2026.

Fresenius SE – Fotorealistisch: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht — Fresenius SE & Co. KGaA (ISIN DE0005785604) ist ein internationaler Gesundheitskonzern mit Sitz in Bad Homburg. Das Unternehmen betreibt Krankenhäuser und entwickelt Arzneimittel und Infusionslösungen. Dieses Bild zeigt: Modernes Krankenhauszimmer mit Patientenmonitor bei Tageslicht, Illustration mit AI erstellt.

Fourteen analysts set an average EUR 55.66 target for Fresenius stock in the consensus cited by MarketScreener on October 16, 2026. The same report said Deutsche Bank kept its Buy rating and a EUR 56.00 target. The consensus target stands 24.19 percent above the Lang & Schwarz price. Fresenius was trading at EUR 44.82 at Lang & Schwarz on October 19, 2026 at 4:39 p.m. CEST, down 0.58 percent versus the Xetra close of October 16, 2026 at EUR 45.08.

Target leaves 24.19 percent upside

The average analyst target gives the stock a measurable valuation reference, while the current quotation remains below both the consensus level and Deutsche Bank's EUR 56.00 target. The difference between the average target and the Lang & Schwarz price is calculated in euros, keeping the comparison separate from the company's operating figures.

The consensus covered 14 analyses, making the EUR 55.66 figure broader than a single-house view. For investors, that distinction matters because the target represents an aggregate view, while Deutsche Bank's EUR 56.00 target is one named bank's assessment.

Stock sits within its yearly range

Fresenius' 52-week range was EUR 35.11 to EUR 52.96 as of October 19, 2026. The Lang & Schwarz price stood 15.37 percent below the high and 27.66 percent above the low. The quote's bid was EUR 44.81 and its ask was EUR 44.84 at 4:39 p.m. CEST.

Trading volume was 220,310 shares on October 19, 2026, compared with an average volume of 1,013,569 shares. That market activity provides a practical context for the day's modest 0.58 percent decline against the Xetra close.

Valuation and November 4 results

Fresenius had a P/E of 16.31 and market capitalization of EUR 25.3 billion as of October 19, 2026. The figures place the stock's current valuation alongside the analyst target rather than treating the target as a guaranteed outcome.

Fresenius lists November 4, 2026 as the date for publication of its third-quarter 2026 financial report. That date is the next scheduled company event in the investor calendar and gives the valuation discussion a defined reporting point.

Price remains below the Xetra close

The stock's position combines a 24.19 percent distance to the average analyst target with a 15.37 percent gap below the 52-week high. The next scheduled results date is November 4, 2026, while the current market value is EUR 25.3 billion.

Fresenius was trading at EUR 44.82 at Lang & Schwarz on October 19, 2026 at 4:39 p.m. CEST, 0.58 percent below the Xetra close of October 16, 2026 at EUR 45.08. The further course of trading is shown by the continuously updated real-time quote of Fresenius stock.